ArticleCaspian journal of internal medicine2026
Bacillus Calmette-Guerin in controlling type 1 diabetes: A quasi-experimental randomized clinical trial.
Article in Caspian journal of internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: T1DM is an autoimmune and chronic metabolic disorder characterized by the destruction of pancreatic beta cells. The Bacillus Calmette--Guérin (BCG) vaccine, originally used for tuberculosis prevention, has shown potential in modulating the immune response and improving beta-cell function. This study aimed to evaluate the therapeutic effects of two doses of BCG vaccine, administered four weeks apart, on glycemic control and selected immunological markers in patients with T1DM. Methods: In this single-center, double-blind randomized clinical trial, 33 patients with T1DM were enrolled and randomly assigned to intervention and control groups in a 1:1 ratio, matched by age and sex. The intervention group received two intradermal doses of the BCG vaccine, with a four-week interval. Fasting blood samples were collected at baseline and during follow-up to assess biochemical and immunological parameters. Patients were followed-up for 18 months. IRCT identifier: IRCT20201012049003N1; (date of registration: 2020/10/15). Results: The mean age of participants was 11.25±3.32 years in the control group and 10.69±3.22 years in the BCG group. Anti-ICA levels significantly decreased in the BCG group by the end of the follow-up period. Although there was no significant difference in fasting blood glucose levels between the two groups, a significant reduction in HbA1c was observed in the BCG group after 18 months. Conclusion: The findings suggest that BCG vaccination may contribute to improved long-term glycemic control, as evidenced by reduced HbA1c levels, in patients with T1DM. Additionally, the decrease in Anti-ICA levels indicates a potential immunomodulatory effect, supporting the therapeutic promise of BCG in autoimmune diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.